

NJC

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Synthesis, antitubercular and antimicrobial activity of 1'-(4-chlorophenyl) pyrazole containing 3,5-disubstituted pyrazoline derivatives

Cite this: DOI: 10.1039/c3nj00000x

Received ooth XXXX 2013,
Accepted ooth XXXX 2013

DOI: 10.1039/c3nj00000x

www.rsc.org/njc

Nandam.Harikrishna^{a, b}, Arun M. Isloor^{a, c*}, K. Ananda^d, AbdulrahmanObaid^e and Hoong-Kun Fun^{e, f}


A new series of 1'-(4-chlorophenyl)-5-(substituted aryl)-3'-(substituted aryl)-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (6a-e), (8a-e), (10a-e) have been synthesized, characterized and screened against antimicrobial and antitubercular activity. Among the synthesized compounds, Minimum Inhibition Concentration of 10e was found to be as low as 1.56 µg/ml and 10c had 6.25 µg/ml as compared to the standard anti-tb drugs Pyrazinamide and Streptomycin.

Mycobacterium Tuberculosis is one among the most dangerous bacteria, which causes the infectious disease and remains out of control in many developing countries.¹ It is a remarkable pathogenic bacteria, that has latently infected inside the body.² The control of the tuberculosis is most challenging in case of multi-drug resistance strains of *Mycobacterium tuberculosis*. The spread of multidrug-resistant TB (MDR-TB) and the appearance of extensively drug-resistant TB (XDR-TB) pose new challenges for the prevention, treatment and control of this deadly disease. Fewer new drugs were approved to treat tuberculosis with very long and complicated therapy.³ It can be treated with multidrug combinations in an average span of six months.²

The azole class of drug derivatives and research has occupied an important role in the medicinal chemistry. Pyrazoles are well known nitrogen containing heterocyclic compounds. As per the literature, pyrazole and its derivatives represents one of the most desirable class of compounds with a wide variety of pharmacological activities viz., antitubercular,^{4,5} antifungal,⁶ antidepressant,^{7,8} antimicrobial,⁹ anti-angiogenic,¹⁰ analgesic,¹¹ anticancer¹² and anticonvulsant.¹³ Moreover, pyrazole containing pyrazoline derivatives are important drug molecules and exhibit an important pharmacophore activities viz. antioxidant,¹⁴ antimicrobial¹⁵ and antidiabetic.¹⁶ Few of the literature reveals that, the presence of substituted phenyl i.e. 4-chlorophenyl or benzene sulfonamide at first position of pyrazole exhibit enhanced biological activities.¹⁷ Based on the above considerations, we hereby report the synthesis of 1-(4-chlorophenyl) pyrazole containing pyrazoline derivatives and its antitubercular activity against *Mycobacterium tuberculosis*.

The targeted compounds 1'-(4-chlorophenyl)-5-(2,3-dihydrobenzofuran-5-yl)-3'-(substituted aryl)-3,4-dihydro-2H, 1'H-[3,4']bipyrazolyl (6a-e), 1'-(4-chlorophenyl)-5-(5-methylfuran-2-yl)-3'-(substituted aryl)-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (8a-e) and

5-biphenyl-4-yl)-1'-(4-chlorophenyl)-3'-(substituted aryl)-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (10a-e) were synthesized according to the steps outlined in Scheme 1.



Where: 2= 5-Acetyl-2,3-dihydrobenzofuran; 3= 5-Acetyl-2-methylfuran; 4= Monoacetyl biphenyl
i= Methanol, cat. NaOH, RT, 4 h; ii= Hydrazine hydrate, Ethanol, Reflux, 3 h.

Scheme 1: Synthetic route for the pyrazole bearing pyrazoline derivatives

The basic pyrazole skeleton i.e. 1,3-disubstituted pyrazole-4-carbaldehydes **1** were synthesized by Vilsmeier-Haack reaction in moderate to good yields.⁹ The other key starting materials 5-acetyl-2,3-dihydrobenzofuran **2**, 2-acetyl-5-methylfuran **3** and 4-monoacetyl biphenyl **4** were prepared as per the reported literature¹⁸ and confirmed by IR and NMR. The 1,3-disubstituted pyrazole-4-carbaldehyde **1** reacted with **2**, **3** and **4** individually to give chalcone derivatives (**5a-e**, **7a-e**, **9a-e**) respectively. Which on reacting with hydrazine hydrate in ethanol media under reflux temperature to give (**6a-e**, **8a-e**, **10a-e**) in reasonable yields.

Formation of **6a-e**, **8a-e**, **10a-e** were confirmed by recording their IR, ¹H NMR, ¹³C NMR and mass spectra. IR analysis of compound **6a** showed the peak at 3322 cm⁻¹ is due to the NH group. The absorption band at 1607cm⁻¹ was due to the -C=N group and -C=C stretching was observed at 1497 cm⁻¹. The ¹H NMR spectrum of **6a** in DMSO-*d*₆ solvent showed a triplet at δ 2.90-2.96 which was attributed to H_A proton, and triplet at δ 3.42-3.49 was due

to the H_B proton of the pyrazoline ring. The characteristic peak of -NH proton of pyrazoline was observed as a singlet at δ 8.62. The detailed ¹H NMR resonances are summarized in the experimental section. The mass spectrum of **6a** showed a molecular ion peak at $m/z = 441.2$ (M⁺). This in turn confirmed the formation of a compound having the molecular formula C₂₆H₂₁ClN₄O. The other compounds **8a-e** and **10a-e** were explained in the supplementary material. The characterization data of the newly synthesized compounds **6a-e**, **8a-e** and **10a-e** were presented in Table 1.

Table 1 Characterization data of the compounds **6a-e**, **8a-e** and **10a-e**

Com poun ds	Ar ₁	Ar ₂	Mol. F/ Mol. wt	M.P (°C)	Color & nature
6a	Phenyl	5-(2,3-dihydrobenzofuran)	C ₂₆ H ₂₁ ClN ₄ O/440.92	156-157	White solid
6b	4-Methylphenyl	5-(2,3-dihydrobenzofuran)	C ₂₇ H ₂₃ ClN ₄ O/454.95	151-153	Off-white solid
6c	4-Methoxyphenyl	5-(2,3-dihydrobenzofuran)	C ₂₇ H ₂₃ ClN ₄ O/470.95	132-134	Off-white solid
6d	2-Chlorophenyl	5-(2,3-dihydrobenzofuran)	C ₂₆ H ₂₀ ClN ₄ O/475.37	171-172	White solid
6e	2-Thiophene	5-(2,3-dihydrobenzofuran)	C ₂₄ H ₁₉ ClN ₄ OS/446.95	140-141	White solid
8a	Phenyl	5-(2-methylfuran)	C ₂₃ H ₁₉ ClN ₄ O/402.88	144-145	White solid
8b	4-Methylphenyl	5-(2-methylfuran)	C ₂₄ H ₂₁ ClN ₄ O/416.90	206-208	Off-white solid
8c	4-Methoxyphenyl	5-(2-methylfuran)	C ₂₄ H ₂₁ ClN ₄ O ₂ /432.9	156-157	Off-white solid
8d	2-Chlorophenyl	5-(2-methylfuran)	C ₂₃ H ₁₈ ClN ₄ O/437.32	198-200	Off-white solid
8e	2-Thiophene	5-(2-methylfuran)	C ₂₁ H ₁₇ ClN ₄ OS/408.9	186-187	Off-white solid
10a	Phenyl	4-(biphenyl)	C ₃₀ H ₂₃ ClN ₄ /474.98	164-165	Off-white solid
10b	4-Methylphenyl	4-(biphenyl)	C ₃₁ H ₂₅ ClN ₄ /489.01	157-158	Off-white solid
10c	4-Methoxyphenyl	4-(biphenyl)	C ₃₁ H ₂₅ ClN ₄ O/505.01	160-162	Off-white solid
10d	2-Chlorophenyl	4-(biphenyl)	C ₃₀ H ₂₂ ClN ₄ /509.43	184-186	Off-white solid
10e	2-Thiophene	4-(biphenyl)	C ₂₈ H ₂₁ ClN ₄ /441.2	217-	Off-white solid

Thiophene	N ₄ S/481.01	219	white solid
-----------	-------------------------	-----	-------------

Antimicrobial activity of all the synthesized compounds were screened against *Staphylococcus aureus* (Gram positive bacteria), *Mycobacterium smegmatis* (tubercular variant), and *Candida albicans* (fungi). The Minimum Inhibitory Concentration (MIC) of all the organisms tested at different concentrations ranging from 500 to 3.9 μ g/ml. Most of the compounds were exhibited the activity with MIC ranging between 62.5 to 7.8 μ g/ml. Structure activity relationship of the synthesized compound was explained based on MIC. The compound **10e** showed lowest MIC against all tested organisms due to the presence of 2-thiophene group at third position of the pyrazole ring and biphenyl at third position of the pyrazoline ring. The second lowest MIC showed for compounds **6a** is due to the presence of 2,3-dihydrobenzofuran at third position of pyrazoline ring and phenyl group at third position of pyrazole, compound **10c** is due to biphenyl at third position of pyrazoline and 4-methoxyphenyl at third position of pyrazole and compound **10d** is due to biphenyl substitution on pyrazoline at third position and *p*-chlorophenyl at third position of pyrazole ring. Other compounds **6d**, **6e**, **8b**, **8c**, **8d** showed moderate activity with MIC value 62.5 to 125 μ g/ml against tested organisms. Antimicrobial results of final compounds **6a-e**, **8a-e**, **10a-e** were tabulated in Table 2.

The MIC against pathogenic bacteria *Mycobacterium tuberculosis* H₃₇Rv at different concentrations ranging from 100 to 0.8 μ g/ml was also represented in Table 2. Most of the compounds were exhibited the activity with MIC ranging between 50 μ g/ml to 1.56 μ g/ml. The compound **10e** showed lowest MIC (1.56 μ g/ml) among all other compounds and it was more active than the standard first-line anti-tb drug Pyrazinamide (MIC value 3.12 μ g/ml). The second lowest MIC (6.25 μ g/ml) obtained for compound **10c** against the tested microorganism and it was similarly active with the standard anti-tb drug Streptomycin (MIC value 6.25 μ g/ml). The compound **6a** showed third lowest MIC (12.5 μ g/ml). Other compounds **6d**, **6e**, **8a**, **8b**, **8c**, **8d** showed moderate activity with MIC value 25 μ g/ml against tested *Mycobacterium tuberculosis*. This indicates that, most of the pyrazole containing pyrazoline compounds with 5-methylfuran substitution at third position is able to give moderate activity against *M. Tuberculosis*. Compounds **6b**, **6c**, **8e**, **10a**, **10b**, **10d** were showing less activity against tested organisms with MIC value 50 μ g/ml.

Table 2: The Minimum Inhibitory Concentration (MIC) of **6a-e**, **8a-e** and **10a-e** against various antimicrobial and antitubercular agents

Synthesized Compound	MIC in μ g/mL			
	<i>M. smegmatis</i>	<i>S. aureus</i>	<i>C. albicans</i>	<i>M. Tuberculosis</i>
6a	15.6	15.6	31.25	12.5
6b	500	500	500	50
6c	500	500	500	50
6d	62.5	62.5	62.5	25
6e	62.5	125	62.5	25
8a	250	125	125	25
8b	62.5	125	62.5	25
8c	62.5	62.5	62.5	25
8d	62.5	62.5	62.5	25
8e	125	31.25	125	50
10a	125	125	125	50
10b	500	500	500	50
10c	15.6	15.6	31.25	6.25
10d	15.6	62.5	31.25	50
10e	7.8	15.6	31.25	1.56
ABS	<5	<5	--	3.12

AFS	--	--	<10	--
PZA	--	--	--	3.12
Streptomycin	--	--	--	6.25

ABS; antibacterial standard Ciprofloxacin; AFS; antifungal standard Fluconazole; PZA; anti-tb standard Pyrazinamide; --: not detected inhibition; control; dimethylsulfoxide

The *in vitro* cytotoxicity study was carried out using HeLa cells at Stellixir Biotech Pvt. Ltd, Bangalore. The five compounds **6a**, **6d**, **8b**, **10c** and **10e** which had highest to moderate activity for antimicrobial and antituberculosis were tested for cytotoxicity with HeLa cells represented in Figure 1. The IC₅₀ value of synthetic compound found to be moderately effective for the HeLa cells. The control cells which are not treated with any compound have shown 100% viability. One of the synthetic compound **8b** has shown highest cytotoxicity (12.83 µg/mL) among tested compounds. The compounds having cytotoxicity below 50 µg/mL IC₅₀ value are usually considered as toxic compounds.




Figure 1: Cytotoxicity of **6a**, **6d**, **8b**, **10c** and **10e** with HeLa cell line

This concludes that, compounds 6a-e, 8a-e and 10a-e derivatives were synthesized, characterized and investigated for their *in-vitro* antimicrobial by Resazurin reduction method and was used for determining the MIC in 96 well microplates.¹⁹ and antitubercular activity by microplate alamar blue assay (MABA) method²⁰ and proved to be very good antimicrobial and antitubercular agents. The results are consistent with specific substitution to utility of tuberculosis chemotherapy and antimicrobial agents. The compounds 10e, 10c showed best screening results among all the synthesized compounds. This indicates, newly synthesized pyrazole containing pyrazoline compounds might emerge as one of the antituberculosis drugs.

Experimental

All the chemicals were purchased from Sigma Aldrich and Spectrochem-India. Melting points were determined by open capillary method and are uncorrected. The IR spectrums (in KBr pellet) were recorded on Perkin-Elmer FTIR-4000-400 cm⁻¹ spectrophotometer. NMR spectra were obtained on a Bruker Avance-400 spectrometer (400 MHz) for ¹H NMR and ¹³C NMR using tetramethylsilane (TMS) as internal standard. The mass spectrum was recorded on LC-MS Applied biosystems MDS SCIEX-API 4000 spectrometer. Elemental analysis was performed

on a Flash EA 1112 series CHNS-O analyzer. The completion of the reaction was checked by thin layer chromatography (TLC) with readymade aluminium sheets (Merck F₂₅₄). The names of the structures were mentioned as per chemdraw.

A mixture of 1,3-disubstituted pyrazole-4-carbaldehyde (**1a-e**) (0.01 mol), acetyl derivative (**2**, **3** and **4**) (0.91 g, 0.01 mol) in ethanol (10 ml) were stirred in the presence of 10% sodium hydroxide solution (2 ml) at an ambient temperature for 5 h. The resultant yellow color reaction mass was filtered and washed with 5 ml of ethanol to get chalcone intermediate (**5a-e**), (**7a-e**) and (**9a-e**) respectively in reasonably good yields (80-95%). The compound (**5a-e**), (**7a-e**) and (**9a-e**) (0.005 mol) was taken in ethanol (10 ml) and added excess amount of hydrazine hydrate (1.3 g, 0.005 mol). The reaction mixture was heated at reflux temperature for 2 h and reaction was monitored by TLC [Hexane : Ethylacetate (4:1)]. The reaction mass was cooled to room temperature and stirred for 0.5 h. The solid product was filtered and washed with ethanol to get (**6a-e**), (**8a-e**) and (**10a-e**) respectively.

1'-(4-chlorophenyl)-5-(2,3-dihydrobenzofuran-5-yl)-3'-phenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (6a). IR (KBr ν_{\max} cm⁻¹): 3322 (N-H str), 3064 (Ar-H str), 2919 (C-H aliphatic str), 1607 (C=N str), 1497 (C=C str), 824 (C-Cl str); ¹H NMR (400 MHz, DMSO-*d*₆, ppm): δ 2.90-2.96 (t, 1H, H_A, *J* = 12.8 Hz), 3.19 (t, 2H, -CH₂), 3.42-3.49 (t, 1H, H_B, *J* = 13.6 Hz), 4.56 (t, 2H, -CH₂), 4.89-4.92 (t, 1H, H_X, *J* = 10.4 Hz), 6.77 (m, 1H, Ar-H), 7.33-7.36 (m, 2H, Ar-H), 7.43-7.56 (m, 6H, Ar-H), 7.77-7.95 (m, 4H, Ar-H), 8.62 (s, 1H, -NH); ¹³C NMR (100 MHz, DMSO-*d*₆, ppm): δ 160.5, 151.2, 138.8, 133.2, 130.7, 130.1, 129.9, 129.7, 129.1, 128.6, 128.4, 128.2, 128.0, 126.3, 122.9, 121.0, 120.2, 109.2, 71.7, 55.5, 29.3; MS: *m/z* = 441.2 (M⁺), ANAL. Calcd. for C₂₆H₂₁ClN₄O; calcd: C, 70.82; H, 4.80; N, 12.71; found: C, 70.83; H, 4.80; N, 12.72.

1'-(4-chlorophenyl)-5-(5-methylfuran-2-yl)-3'-phenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (8a). IR (KBr ν_{\max} cm⁻¹): 3316 (N-H str), 3117 (Ar-H str), 2923 (C-H aliphatic str), 1594 (C=N str), 1499 (C=C str), 829 (C-Cl str); ¹H NMR (400 MHz, DMSO-*d*₆, ppm): δ 2.31 (s, 3H, -CH₃), 2.84-2.90 (t, 1H, H_A, *J* = 13.0 Hz), 3.31 (m, 1H, H_B), 4.89-4.95 (t, 1H, H_X, *J* = 10.6 Hz), 6.17 (s, 1H, Ar-H), 6.50 (s, 1H, Ar-H), 7.44-7.76 (m, 8H, Ar-H), 7.94-7.95 (d, 2H, Ar-H, *J* = 6.0 Hz), 8.59 (s, 1H, -NH); ¹³C NMR (100 MHz, DMSO-*d*₆, ppm): δ 152.9, 151.1, 147.3, 142.1, 138.7, 133.2, 130.7, 129.9, 129.1, 128.6, 128.4, 128.0, 123.7, 120.2, 110.9, 108.3, 55.2, 13.9; MS: *m/z* = 403.2 (M⁺), ANAL. Calcd. for C₂₃H₁₉ClN₄O; calcd: C, 68.57; H, 4.75; N, 13.91; found: C, 68.60; H, 4.76; N, 13.92.

5-Biphenyl-4-yl-1'-(4-chlorophenyl)-3'-phenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazolyl (10a). IR (KBr ν_{\max} cm⁻¹): 3312 (N-H str), 3073 (Ar-H str), 2921 (C-H aliphatic str), 1593 (C=N str), 1497 (C=C str), 830 (C-Cl str); ¹H NMR (400 MHz, DMSO-*d*₆, ppm): δ 2.97-3.03 (dd, 1H, H_A, *J* = 10.9 Hz), 3.49-3.56 (dd, 1H, H_B, *J* = 10.7 Hz), 4.97-5.03 (dt, 1H, H_X), 7.30-7.38 (m, 2H, Ar-H), 7.45-7.55 (m, 6H, Ar-H), 7.64-7.65 (d, 1H, Ar-H, *J* = 3.3 Hz), 7.68 (s, 1H, pyrazole-5H), 7.70-7.71 (dd, 5H, Ar-H, *J* = 1.4 Hz), 7.80-7.82 (d, 2H, Ar-H, *J* = 8.5 Hz), 7.89-7.91 (d, 2H, Ar-H, *J* = 7.7 Hz), 8.61 (s, 1H, -NH); MS: *m/z* = 475.1 (M⁺), ANAL. Calcd. for C₃₀H₂₃ClN₄; calcd: C, 75.86; H, 4.88; N, 11.80; found: C, 75.90; H, 4.90; N, 11.90.

Acknowledgments

AMI thank, Director, National Institute of Technology Karnataka, India for providing the research facilities. The authors extend their appreciation to The Deanship of Scientific Research at King Saud University for funding the work through research group project no. RGP-VPP-207.

Notes and references

^aMedicinal Chemistry Laboratory, Department of Chemistry, National Institute of Technology Karnataka, Surathkal, Mangalore 575025, India.

^bSeQuent Scientific Limited, Baikampady, Mangalore 575011, India.

^cDepartment of Chemistry, Indian Institute of Information Technology Dharwar, India

^dBiological Sciences, Poornaprajna Institute of Scientific Research, Bangalore 562110, India.

^eDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box. 2457 - Riyadh 11451, Kingdom of Saudi Arabia.


^fX-ray Crystallography Unit, School of Physics, Universiti Sains Malaysia, Penang 11800, Malaysia.

† Footnotes should appear here. These might include comments relevant to but not central to the matter under discussion, limited experimental and spectral data, and crystallographic data.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/c000000x/

1. A. Konstantinos, *Australian prescriber*, 2010, **33**, 12-18.
2. Y. Zhang, K. Post-Martens and S. Denkin, *Drug Discovery Today*, 2006, **11**, 21-27.
3. V. Bhowruth, L. G. Dover and G. S. Besra, *Prog. Med. Chem.*, 2007, **45**, 169-203.
4. N. K. Piyush, P. S. Shailesh and K. R. Dipak, *New J. Chem.*, 2014, **38**, 2902-2910.
5. R. A. Gupta and S. G. Kaskhedikar, *Med. Chem. Res.*, 2013, **22**, 3863-3880.
6. P. Horrocks, M. R. Pickard, H. H. Parekh, S. P. Patel and R. B. Pathak, *Org. Biomol. Chem.*, 2013, **11**, 4891-4898.
7. M. A. Abdel, G. R. Abou and A. A. Hassan, *Eur. J. Med. Chem.*, 2009, **40**, 3480-3487.
8. E. Palaska, M. Aytemir, I. T. Uzbay, D. Erol, *Eur. J. Med. Chem.*, 2001, **36**, 539-543.
9. N. Harikrishna, A. M. Isloor, K. Ananda, A. Obaid and H. K. Fun, *RSC Adv.*, 2015, **5**, 43648-43659.
10. M. S. Christodoulou, S. Liekens, K. M. Kasiotis and S. A. Haroutounian, *Bioorg. Med. Chem.*, 2010, **18**, 4338-4350.
11. A. M. Isloor, B. Kalluraya and M. Rao, *J. Saudi Chem. Soc.*, 2000, **4**, 265-270.
12. I. Koca, A. Ozgur, K. A. Coskun and Y. Tutar, *Bioorg. Med. Chem.*, 2013, **21**, 3859-3865.
13. Z. ZuhailOzdemir, H. B. Kandilci, B. Gumusel, U. Calis and A. Bilgin, *Eur. J. Med. Chem.*, 2007, **42**, 373-379.
14. V. H. S. Jois, B. Kalluraya and K. S. Girisha, *J. Ser. Chem. Soc.*, 2014, **79**, 1469-1475.
15. P. T. Chovatia, J. D. Akabari, P. K. Kachhadia, P. D. Zalavadia and H. S. Joshi, *J. Ser. Chem. Soc.*, 2007, **71**, 713-720.
16. H. G. Garg and P. P. Singh, *J. Chem. Soc. C.*, 1969, 1141-1143.
17. F. A. Ragab, N. M. A. Gawab, H. H. Georgey and M. F. Said, *Eur. J. Med. Chem.*, 2013, **63**, 645-654.
18. R. J. Alabaster, I. F. Cottrell, H. Marley and S. H. B. Wright, *Synthesis*, 1988, 950-952.
19. F. V. Driessche, P. Rigole, G. Brackman and T. Coenye, *J. Microbiol Methods*, 2014, **98**, 31-34.
20. M. C. S. Lourenco, M. V. N. deSouza, A. C. Pinheiro, M. L. Ferreira, B. Rasnisb, Goncalves, T. C. M. Nogueira and M. A. Peralta, *Arkivoc.*, 2007, **XV**, 181-191.

Drugs of Pyrazinamide and Streptomycin.



New series of pyrazoline derivatives was synthesized and characterized by spectral techniques. Synthesized compounds were evaluated for their antitubercular and antimicrobial activities. Most of the compounds are found to be biologically potent.